April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Müller Cells in Macular Pathology
Author Affiliations & Notes
  • M. B. Powner
    Cell Biology, UCL Institute of Ophthalmology, London, United Kingdom
  • M. C. Gillies
    Save Sight Institute, University of Sydney, Sydney, Australia
  • M. Tretiach
    Save Sight Institute, University of Sydney, Sydney, Australia
  • A. Scott
    Cell Biology, UCL Institute of Ophthalmology, London, United Kingdom
  • R. H. Guymer
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia
  • G. S. Hageman
    John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Utah, Utah
  • M. Fruttiger
    Cell Biology, UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships  M.B. Powner, None; M.C. Gillies, None; M. Tretiach, None; A. Scott, None; R.H. Guymer, None; G.S. Hageman, None; M. Fruttiger, None.
  • Footnotes
    Support  Lowy Medical Research Institute LTD, Fight for Sight (UK), NIH R24 EY017404 (GSH), Grant to the University of Iowa Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5761. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. B. Powner, M. C. Gillies, M. Tretiach, A. Scott, R. H. Guymer, G. S. Hageman, M. Fruttiger; Müller Cells in Macular Pathology. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5761.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To assess the histopathological changes in a postmortem sample derived from an eye donor with Macular Telangiectasia Type 2 (MacTel type 2) to gain further insight into the cause of the disease. MacTel type 2 affects such a specific region around the fovea that is consistent in terms of clinical observations between patients, the specificity of this region might be due to anatomical/biochemical differences in the macula compared to the rest of the retina.

Methods: : Macular pigment distribution of freshly dissected eyes was photographed. Sections of the retina-RPE-choroid complex from both the macular and peripheral regions were assessed using antigen retrieval and immunohistochemistry to study the distribution of cell-specific markers for blood vessels, glial cells, microglia and photoreceptors. Using anatomical landmarks the sections were matched with the macular pigment distribution and a fluorescein angiogram that was taken before the donors’ death.

Results: : Macular pigment was absent in the macula. Abnormally dilated capillaries were indentified in a macula that correlated spatially with regions of fluorescein leakage in an angiogram that was taken 12 years prior to death. These telangiectatic vessels displayed a marked reduction of the basement membrane component collagen IV, indicating vascular pathology. GFAP was limited to retinal astrocytes and no reactive Müller cells were identified. Importantly, reduced immunoreactivity with Müller cell markers (vimentin, glutamine synthetase and retinaldehyde binding protein) in the macula was observed, which correlated to the region of depleted macular pigment.

Conclusions: : These findings suggest that macular Müller cell loss or dysfunction is a critical component of MacTel type 2, which may have implications for future treatment strategies. Due to the spatially restricted pathology in MacTel type 2, we also conclude that the specificity of the disease area implies that there is a fundamental biological or biochemical difference between the retina in the macula and the periphery.

Keywords: macula/fovea • Muller cells • pathobiology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.